Report Detail

Pharma & Healthcare Partnerships, Licensing, Investments and M&A Deals and Trends for September 2018 in Pharmaceuticals

  • RnM2839520
  • |
  • 30 January, 2019
  • |
  • Global
  • |
  • 78 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Partnerships, Licensing, Investments and M&A Deals and Trends for September 2018 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for September 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2018. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


1 Table of Contents

    1 Table of Contents 2

    • 1.1 List of Tables 5
    • 1.2 List of Figures 7

    2 Pharmaceuticals & Healthcare, Global, Deal Summary 11

    • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2018 11
    • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, September 2018 13
      • 2.2.1 AbbVie Raises USD6 Billion in Public Offering of Notes 13
      • 2.2.2 Pfizer Raises USD5 Billion in Public Offering of Notes 14
      • 2.2.3 Abbott Labs Raises USD4 Billion in Public Offering Bonds 14
      • 2.2.4 Alexion Pharma Acquires Syntimmune 14
      • 2.2.5 Aurobindo Pharma USA to Acquire Dermatology Generics Business from Sandoz 14
    • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2018 16
    • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2018 17

    3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 18

    • 3.1 Pharmaceuticals & Healthcare, Global, M&A, September 2018 18
      • 3.1.1 Top M&A Deals in September 2018 19
      • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2018 - September 2018 20
    • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2018 21
      • 3.2.1 Top Equity Offering Deals in September 2018 22
      • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, April 2018 - September 2018 23
    • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, September 2018 24
      • 3.3.1 Top PE/VC Deals in September 2018 25
      • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, September 2018 26
      • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2018 27
      • 3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, April 2018-September 2018 29
      • 3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, April 2018-September 2018 30
    • 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, September 2018 31
    • 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, April 2018 - September 2018 32
    • 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), September 2018 33
      • 3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, September 2018 34
    • 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2018 - September 2018 35
    • 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, April 2018 - September 2018 36
    • 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), April 2018 - September 2018 37
    • 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), April 2018 - September 2018 38

    4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2018 39

    • 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, September 2018 39
    • 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2018 40
    • 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), April 2018 - September 2018 41
    • 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), April 2018 - September 2018 42
    • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), April 2018 - September 2018 43
    • 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), April 2018 - September 2018 45
      • 4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, September 2018 46
      • 4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, September 2018 46
      • 4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2018 47

    5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 48

    • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, September 2018 48
      • 5.1.1 Oncology - Deals of the Month 49
    • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, September 2018 51
      • 5.2.1 Central Nervous System - Deals of the Month 52
    • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, September 2018 53
      • 5.3.1 Infectious Diseases - Deals of the Month 54
    • 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, September 2018 55
      • 5.4.1 Cardiovascular - Deal of the Month 56
    • 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, September 2018 57
      • 5.5.1 Immunology - Deal of the Month 58
    • 5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, September 2018 59
      • 5.6.1 Gastrointestinal - Deal of the Month 60
    • 5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, September 2018 61
      • 5.7.1 Metabolic Disorders - Deal of the Month 62

    6 Deal Summary by Geography 64

    • 6.1 Pharmaceuticals & Healthcare, North America Deals, September 2018 64
      • 6.1.1 North America - Deals of the Month 65
    • 6.2 Pharmaceuticals & Healthcare, Europe, Deals, September 2018 67
      • 6.2.1 Europe - Deals of the Month 68
    • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, September 2018 70
      • 6.3.1 Asia-Pacific - Deals of the Month 71
    • 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, September 2018 73
      • 6.4.1 Rest of the World - Deals of the Month 74

    7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 75

    • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, April 2018 - September 2018 75
    • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, April 2018 - September 2018 76

    8 Further Information 77

    • 8.1 Methodology 77
    • 8.2 About GlobalData 78
    • 8.3 Contact Us 78
    • 8.4 Disclosure information 78

    Summary:
    Get latest Market Research Reports on Partnerships, Licensing, Investments and M&A Deals and Trends for September 2018 in Pharmaceuticals. Industry analysis & Market Report on Partnerships, Licensing, Investments and M&A Deals and Trends for September 2018 in Pharmaceuticals is a syndicated market report, published as Partnerships, Licensing, Investments and M&A Deals and Trends for September 2018 in Pharmaceuticals. It is complete Research Study and Industry Analysis of Partnerships, Licensing, Investments and M&A Deals and Trends for September 2018 in Pharmaceuticals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $1,000.00
    $2,000.00
    $3,000.00
    798.00
    1,596.00
    2,394.00
    933.00
    1,866.00
    2,799.00
    153,760.00
    307,520.00
    461,280.00
    83,460.00
    166,920.00
    250,380.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report